1. Scrip
  2. >>New Products

Celgene, Agios Ready For Enasidenib Launch After Early Approval

 
• By Joseph Haas

Idhifa is the first treatment for AML patients with IDH2 mutations. The drug will be co-commercialized by Celgene and Agios under their 2010 collaboration and is the latter's first regulatory approval.

Digital illustration of Cancer cell in colour background

Celgene Corp. and partner Agios Pharmaceuticals Inc. are ready to quickly capitalize on FDA approval of Idhifa (enasidenib), which came nearly a month earlier than its Aug. 30 priority review user fee date, for a subset of relapsed or refractory acute myeloid leukemia patients, giving Agios its first approved drug and Celgene the initial fruits of a collaboration inked in 2010.

Idhifa, an oral, targeted inhibitor of the isocitrate dehydrogenase-2 (IDH2) enzyme, was approved Aug.1 to treat adult AML patients with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas

 
• By Jessica Merrill

Ultragenyx updated investors on interactions with the US FDA on gene therapy, while new drug launches were themes for Ionis and Organon in Q2 reporting.

Pipeline Watch: Ten Approvals And Fourteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By Joseph Haas

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

More from Scrip

HHS mRNA Vaccine Wind-Down Has Limited Impact (And One Contract Isn’t Even mRNA)

 
• By Alaric DeArment

The news will have a big impact on pandemic preparedness but less immediate financial impact. Tiba Biotech was even “caught off guard” by its inclusion in the department’s culling of mRNA vaccine projects under BARDA, as its project was neither a vaccine nor mRNA-based.

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 
• By Andrew McConaghie

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Can Bayer’s Pharmaceuticals Division Help It Weather A Perfect Storm?

 
• By Aakash Babu

Bayer continues to keep faith in its pharmaceuticals business despite a plethora of problems for the wider group with job cuts, continued debt concerns and ongoing glyphosate litigation claims.